Kornimate/medical-research-clean huggingface dataset:
visumax femtolasik versus moria m2 microkeratome in myopia

Conditions: Lasik in Myopia

Summary: this is an interventional prospective clinical study which was conducted to evaluate the efficacy, safety, predictability, ocular aberrations, and flap thickness predictability of visumax femtosecond laser (fsl) compared to moria m2 microkeratome (mk) in mild to moderate myopia.

this study included 60 eyes who were divided into two groups. thirty eyes in group (i) in which the flap was created with visumax fsl, while in group ii (30 eyes) the moria m2 mk was used. keratometric, refractive, and aberrometric measurements were compared preoperatively and 3 months postoperatively. the intraoperative subtraction pachymetry (the sp 100 handy pachymeter (tomey, nagoya, japan) was used for preoperative pachymetry and flap thickness measurement.

Eligibility criteria:
inclusion criteria: * male and female patients were eligible for the study if they were older than 18 years and younger than 40 years. * stable myopia up to -6.0d and astigmatism up to -3.0d determined by manifest refraction for at least 6 months. * best corrected distance visual acuity of at least 20/20, and stable keratometry after cessa¬tion of soft contact lens wear for at least 2 weeks. exclusion criteria: * any anterior seg¬ment pathology. * any form of retinal degeneration. unstable myopia. * severe dry eye. * corneal thickness that would have resulted in less than 300 µm residual stromal thickness. * patients who had keratoconus or were keratoconus suspects. * previous ocular sur¬gery. * a history of herpes zoster ophthalmicus or herpes simplex keratitis. * a history of a steroid-responsive rise in in¬traocular pressure (iop) or a preoperative iop of more than 21 mmhg. * diabetes mellitus, autoimmune dis¬ease, connective tissue disease, and chronic use of systemic corticosteroid or immunosuppressive therapy were also excluded from the study.
interferon-gamma with interferon alpha and ribavirin for hepatitis c non-responders

Conditions: Hepatitis C; Genotype 3; Non-responders; Relapsers

Summary: when administered simultaneously, interferon-alpha 2b + interferon-gamma result in dramatic antiviral synergy.ribavirin has shown to enhance interferon-gamma levels in patients with chronic hepatitis c treated with interferon-alpha. enhancement of immune responses, especially those related to type-1 t helper cell activity, may contribute to better efficacy in combining ribavirin with ifn-alpha for treatment of chronic hepatitis c. the aim of the present study is to evaluate the efficacy and safety of a triple regimen, a combination treatment with interferon gamma, interferon alfa-2b plus ribavirin in patients who have not previously responded to interferon alpha in combination of ribavirin.


Eligibility criteria:
inclusion criteria: * non-responders and relapsers to previous interferon and ribavirin therapy given for six months * hcv genotype 3 * compensated liver disease * hb ≥10 g/dl (females),≥11 g/dl (males) * platelets count ≥ 100,000 / cubic mm * neutrophils count ≥1,500/cubic mm * ≥18 years to ≤ 70 years. * at least one abnormal alt value in the last year. * tsh level within normal limits. * non pregnant adult females. * absence of drug or alcohol abuse. * informed consent given by the patient exclusion criteria: * patient younger than 18 yrs and older than 70 yrs. * hepatitis b or hiv co-infection. * severe renal dysfunction or creatinine clearance less than 50 ml/min * pregnant women or breast feeding women. * suspected hypersensitivity to interferon alpha, gamma or ribavirin. * decompensated liver cirrhosis. * history or any other evidence of other causes of cld other than hepatitis c infection ( like hemochromatosis,, autoimmune hepatitis, metabolic liver disease, alcoholic liver disease, toxin exposure, wilson's disease,drug induced liver disease) * active malignant disease. * any known pre-existing medical condition that could interfere with subject's participation or completion of study such as psychiatric condition, seizures disorder requiring medications, co existing heart diseases, lung diseases, poorly controlled diabetes, auto immune diseases, gout) * history of interferon and/or ribavirin intolerance
clonal architecture of asxl1-mutated myelofibrosis

Conditions: Myelofibrosis

Summary: prospective study to decipher the clonal architecture of asxl1-mutated primary and secondary myelofibrosis and its impact on prognosis

the clonal architecture of myelofibrosis patients is still little described. inconsistent results in terms of the prognostic value of some mutations are observed in the literature, in particular concerning asxl1 mutations. we assume that a better understanding of the clonal architecture of asxl1-mutated myelofibrosis could help refining the prognostic impact of asxl1 mutations. this study aims to evaluate a multicenter cohort of 50 patients. blood of patients will be collected within 18 months of diagnosis. after 4 years of follow-up of the patient as part of his usual care, data on survival and leukemic transformation will be collected.

Eligibility criteria:
inclusion criteria: * adults (age ≥18 years), * affiliated to the national social security system, * asxl1 mutated primary or secondary myelofibrosis, * signed the consent to participate in the study, * included, or consenting to be included, in the national clinical-biological database of france intergroupe syndrome myéloprolifératifs (fim). exclusion criteria: * patient with another active hematological disease or cancer at the time of diagnosis, * person subject to legal protection scheme or incapable of giving consent.
use of a hyperinsulinemic-hypyglycemic clamp to study hypoglycemia: a method development study

Conditions: Diabetes

Summary: a hyperinsulinemic-hypoglycemic clamp is an experimental procedure, which allows for hypoglycemia to be studied in a safe and controlled manner. the goal of this study is to establish the hyperinsulinemic-hypoglycemic clamp procedure at pennington biomedical research center in order to apply the knowledge gained to future studies which will determine the efficacy of our biomarker for predicting susceptibility to hypoglycemia. additionally, our use of continuous glucose monitoring (cgm) during the clamp procedure will provide novel data regarding the accuracy of cgm during hypoglycemic conditions in a controlled research setting.


Eligibility criteria:
inclusion criteria: * healthy male or female * ages 18-40 years * bmi between 20 kg/m2 and 30 kg/m2 (±0.5 kg/m2 will be accepted) * medically cleared for participation in the study exclusion criteria: * history of clinically diagnosed diabetes or a fasting blood glucose \>126 mg/dl * average screening blood pressure \>140/90 mmhg * history of cardiovascular disease * pregnant, planning to become pregnant, or breastfeeding * based on the investigative team's clinical judgement, a subject may not be appropriate for participation in the study.
quality of life 12 months after cardiac surgery

Conditions: Quality of Life

Summary: cardiac surgical patients entering the hospital for operation were voluntarily recruited to participate a 12 month follow- up of health related quality of life (qol)

cardiac surgical patients entering the hospital for operation were voluntarily recruited to participate a 12 month follow- up of health related quality of life based on established qol measurements with euroqol quality of life 5 dimensional 3 level (eq-5d-3l) description system at preoperative, 6 months and 12 months postoperatively. the study started on may 2013 and ended at the end of 2018. the data has been analyzed for publication in 2021. the total number of patients reached 1594.

Eligibility criteria:
inclusion criteria: * elective or urgent cardiac surgery (open heart procedure to valves or ascending aorta /arch, on-pump or off-pump surgery to the coronary arteries ) * willingness to participate, * ability to comprehend finnish language exclusion criteria: * emergency surgery (with no time to introduce the study in good time) * not willing to participate, * blind or other disturbance in seeing, * inability to comprehend finnish language

Keywords: quality of life, postoperative
pilot study for hypothermia treatment in hyperammonemic encephalopathy in neonates and very young infants

Conditions: Urea Cycle Disorders; Organic Acidemias

Summary: this is a pilot study which will test the safety and feasibility of hypothermia treatment as adjunct therapy to conventional treatment of hyperammonemic encephalopathy (hae) in neonates versus conventional treatment (dialysis, nutritional therapy, and ammonia scavenging drugs) only. the endpoint of the pilot study will be reached when either 24 patients have been enrolled and no serious adverse events were observed, when no patient has been enrolled in 5 years, or when serious adverse events occur which are clearly linked to the use of hypothermia. these would be serious complications not seen in patients on conventional therapy (dialysis , nutritional therapy, ammonia scavenging drugs) for hae.

children with neonatal onset urea cycle disorders or organic acidemias develop hyperammonemia (high ammonia levels) and fall into coma often causing brain damage. for these children to be able to benefit maximally from available long-term treatment and solid organ transplant, outcome of the neonatal onset crisis must be improved. animal experiments and small clinical trials have indicated that hypothermia protects the brain during hyperammonemia. this pilot study investigates whether adjunct hypothermia therapy in addition to standard of care treatment is feasible and safe in babies with high ammonia levels in coma.

Eligibility criteria:
inclusion criteria: * newborns \>36 wks gestation and ≥2200g birth weight without co-morbidity (see exclusion criteria) that have clinical signs and symptoms of an urea cycle disorders or propionic , methylmalonic, or isovaleric acidemia and hyperammonemia and encephalopathy requiring renal replacement therapy. exclusion criteria: * patients with hyperammonemia that have clinical signs and symptoms of lysinuric protein intolerance, mitochondrial disorders, congenital lactic acidosis, and fatty acid oxidation disorders, patients with rare and unrelated serious comorbidities and other genetic diseases, e.g., down syndrome, intraventricular hemorrhage in the newborn period, traumatic brain injury, and low birth weight (\ 36 wks gestation). * infants in extremis for which no additional intensive therapy will be offered by the attending neonatologist.

Keywords: high ammonia level hyperammonemia poor suck lethargy coma encephalopathy seizures brain edema urea cycle disorder ornithine transcarbamylase deficiency carbamoyl phosphate synthetase deficiency citrullinemia argininosuccinic aciduria organic acidemia propionic aciduria methylmalonic aciduria isovaleric aciduria
validation of a molecular signature for early detection of colorectal cancer

Conditions: Colorectal Cancer Screening; Advanced Adenomas (AA)

Summary: the goal of this multicentre and international prospective study is to validate a molecular signature using plasma samples in average-risk population for colorectal cancer who undergo colonoscopy in a screening setting. the main question it aims to answer is: does molecular signature in plasma sample have higher diagnostic accuracy than fit for early detection of colorectal cancer? participants who already have a colonoscopy as part of their regular medical care for colorectal cancer screening will provide a stool sample and a plasma sample.


Eligibility criteria:
inclusion criteria: * participants between the ages of 50 and 75 (both included) at the time of informed consent signed. they must understand the nature, significance, implications and risks of the clinical trial and must sign the informed consent form. * participants referred to the gastroenterology service who are going to undertake colonoscopy as a regular procedure for screening setting. * participants asymptomatic, average risk for crc. average risk is defined as those individuals who are age 50 or older with no history of adenoma, colorectal cancer, or inflammatory bowel disease, and with no family history of crc (first degree relatives). exclusion criteria: * participants between the ages of 50 and 75 (both included) at the time of informed consent signature. they must understand the nature, significance, implications and risks of the clinical trial and must sign the informed consent form. * participants who have been diagnosed with crc. the diagnosis must be subsequently confirmed by biopsy or surgery and pathological anatomy analysis during the study.

Keywords: colon and rectum cancer in vitro diagnostic liquid biopsy screening programme
promoting smoking cessation and reducing weight gain

Conditions: Cardiovascular Diseases; Heart Diseases

Summary: to test whether a behavioral intervention could indeed achieve the dual goals of promoting smoking cessation and minimizing weight gain.

background: when the study began in 1995, more females were initiating cigarette smoking, and a growing proportion cited fear of gaining weight as a major reason for refusing to even attempt quitting smoking. it had not yet been possible, however, to prevent post- cessation weight gain through dieting or behavioral treatment without undermining abstinence from smoking. the investigators proposed that prior interventions had been unsuccessful because: (a) their weight management interventions were too complex; (b) the programs thwarted a need of the patient in nicotine withdrawal to eat hedonically appealing, high-carbohydrate snacks; and (c) the programs heightened patients' emphasis on weight control at the expense of their emphasis on smoking cessation by asking them to initiate weight control before or simultaneously with quitting smoking. design narrative: the investigators collected pilot data on a promising 16-week intervention that they called the late weight plan because it emphasized smoking cessation for the first half of treatment and integrated weight management for the last half. the weight management module included a pre-packaged meal plan; high-carbohydrate, low-fat snacks; and low-intensity aerobic exercise. all patients continued in the weight management phase of treatment, regardless of whether they had succeeded in quitting smoking or were preparing to make new quit attempts. based on pilot findings, the investigators estimated the point prevalence of smoking cessation for the late weight plan group to be 74% at the end of treatment, with weight gain less than 5 lb. an early weight plan group controlled for the timing of the intervention, using the same target quit smoking date and 16 week program but integrating the weight management module into the first 8 weeks of treatment. like others, they found that early weight management efforts, while they may have prevented weight gain, apparently did so at some cost to smoking cessation, which they estimated to be 42% at 4 months. finally, a cessation only group controlled for the presence of a weight management intervention, by dealing exclusively with smoking cessation for the entire 16 week program. the cessation only group had attained the worst outcome in terms of weight control and an intermediate outcome in terms of abstinence at the end of treatment (50%). by randomizing 315 female smokers to the three treatments and comparing abstinence and weight gain after 4 months of treatment and 6 month follow-up (10 months), they tested whether a behavioral intervention could indeed achieve the dual goals of promoting smoking cessation and minimizing weight gain. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
a total of 315 female smokers.
fluoroscopic &ultrasonographic guidance of superior hypogastric plexus neurolysis in intractable pelvic pain

Conditions: Intractable Pelvic Cancer Pain

Summary: fluoroscopic group \& includes 30 patients where shpb will be done fluoroscopic-guided (the posterior oblique trajectory technique.the double modality group \& includes 30 patients where shpb will be done using our described new technique of performing the modified mishra technique by injecting 3-5 ml of contrast media (lohexol=omnipaque) after getting the target position.


Eligibility criteria:
inclusion criteria: * age \> 18 years. * intractable pelvic cancer pain (vas \> 40 mm) * pain is refractory to pharmacotherapy (both opioids and adjuvant therapy) or opioids' side effects are not tolerated. exclusion criteria * local or systemic sepsis. * uncorrectable coagulopathy. * neuropsychiatric illness. * history of drug abuse. * pregnant or lactating patients. * distorted local anatomy. * patients who are known to be allergic to the used medications. * cardiovascular or respiratory instability.
effects of strength and balance training to reduce the fall risk in knee osteoarthritis patients

Conditions: Sports Physical Therapy

Summary: this study will address the scarcity of research and the variations in recommendations regarding the effects of strength and balance training to reduce the fall risk in knee osteoarthritis patients.

this study will be conducted in alkhidmat raazi hospital. written informed consent for inclusion in the study was taken. patients of experimental group will receive balance training with conventional along with tens, heating pad for one hour 3 times weekly. assessment will be performed pre and post of intervention. intervention will be given 3 days a week for 8 weeks.

Eligibility criteria:
inclusion criteria: * age from 55 and 80 year * both male and female patients. * participants will need to have had knee pain for at least 6 months and experience current average pain of at least 3 (on an 11-point numerical pain rating scale (nrs) * patients having no other physical and mental illness. * osteoarthritis of knee (stage-ii) by kallgren and lawrence scale exclusion criteria: * patients with lab results abnormal (malignancy) * nonmusculoskeletal conditions * patient's undergone surgery of knee. * other than osteoarthritis
a safety and efficacy study of setipiprant tablets in androgenetic alopecia in males

Conditions: Alopecia

Summary: this study will evaluate the safety, tolerability and efficacy of the oral administration of setipiprant tablets 1000 mg twice daily (bid) relative to placebo in 18 to 49 years old males with androgenetic alopecia (aga).


Eligibility criteria:
inclusion criteria: * participant has androgenetic alopecia (aga) * participant agrees to maintain current hair care regimen, refraining from hair weaving, hair colorants or dyes and non-study hair growth products during the study. exclusion criteria: * history of hair loss for reasons other than aga * scarring of the scalp or any condition or disease of the scalp, hair or hair shaft * use of products within 6 months of study start used continuously for at least 1 month that could impact hair growth * hair-weaving within 6 months * use of hair colorants or dyes within 6 months.
the effectiveness of using preventive multimedia teaching program in lung cancer women receiving targeted therapy on skin-related quality of life

Conditions: Lung Cancer

Summary: the effectiveness of using preventive multimedia teaching program in lung cancer women receiving targeted therapy on skin-related quality of life


Eligibility criteria:
inclusion criteria: 1. patients older than 20 years of age. 2. the first time to accept the target drug treatment (iressa, tarceva) treatment, diagnosis of lung cancer third or fourth stage of the women. 3. there are computer equipment at home to play the disc. 4. can speak, write, read chinese, clear consciousness, no cognitive impairment. 5. in the medical center of taipei, a medical department, medical or surgical clinic for treatment. exclusion criteria: * none
interpersonal psychotherapy for depressed adolescents and parents

Conditions: Major Depression; Dysthymic Disorder; Adjustment Disorders; Depressive Disorder Not Otherwise Specified

Summary: the purpose of this study is to examine the feasibility and acceptability of an adaptation of interpersonal psychotherapy for depressed adolescents (ipt-a) that includes greater and more structured involvement of the parents in the treatment.

adolescent depression is a significant public health problem, and it increases the risk of poor psychosocial outcomes in adolescence and adulthood. interpersonal psychotherapy for depressed adolescents (ipt-a) has been found to be an effective treatment for reducing adolescents' depressive symptoms and improving their global and social functioning. the purpose of the current study is to examine the feasibility and acceptability of ipt-a when it is delivered with greater and more structured involvement of the parents in the treatment. participants will receive 15 weeks of interpersonal psychotherapy for depressed adolescents and parents (ipt-ap). eight the therapy sessions are conducted with the adolescent individually, two are with the parent(s) individually, and five are conducted with the adolescent and parent(s) together. at the end of the 15 weeks, participants who have demonstrated at least a 50% reduction in depressive symptoms will participate in three booster sessions delivered on a monthly basis. all participants will be assessed at baseline, week 5, week 10, week 15 (post-treatment), and 3 months post-treatment to measure depressive symptoms, global and social functioning, and attitudes toward treatment.

Eligibility criteria:
inclusion criteria: * meets diagnostic criteria for major depression, dysthymic disorder, depressive disorder not otherwise specified, or adjustment disorder with depressed mood * score between 10 and 28 on the hrsd * score of 65 or less on the c-gas * english-speaking adolescent * parental or legal guardian consent to participate exclusion criteria: * actively suicidal * score greater than 28 on the hrsd * mentally retarded * meets diagnostic criteria for current substance abuse, schizophrenia, bipolar disorder, psychosis, conduct disorder, or eating disorder * currently in active treatment for depression * taking antidepressant medication at the time of baseline assessment * medical illness likely to complicate or interfere with treatment * victim of ongoing or previously undisclosed child abuse * parent psychiatrically hospitalized within the past 3 months

Keywords: major depression dysthymic disorder adjustment disorder with depressed mood depressive disorder not otherwise specified adolescent psychotherapy
amrubicin (amr) trial in patients with non-small cell lung cancer

Conditions: Lung Cancer

Summary: the study is to evaluate the effect of amrubicin (amr) compared to docetaxel (doc) in the treatment of non-small cell lung cancer (nsclc).


Eligibility criteria:
inclusion criteria: * histological or cytological diagnosis of non-small cell lung cancer (nsclc) * 1 or 2 prior chemotherapy regimen including 1 platinum-based chemotherapy * 20 or older but younger than 75 years of age exclusion criteria: * symptomatic brain metastasis * interstitial pneumonia or pulmonary fibrosis * abnormal cardiac function or myocardial infraction within 6 months before study enrollment * active infection